Merck & Company Inc is trading 3.1% down at $111.83 despite announcing expanded FDA approval for its CAPVAXIVE pneumococcal vaccine in high-risk children and adolescents.

  • The move suggests investors may be taking profits after recent strength or reassessing valuation amid broader market gains.
  • Merck is underperforming major U.S. indices today despite the positive regulatory news and a lack of negative company-specific headlines.